2 news items
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
VANI
13 May 24
have initiated preclinical activities for NPM-115, our high-dose exenatide implant to support clinical investigations. An Investigational New Drug
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VANI
26 Mar 24
are on track to submit a new Investigational New Drug Application for NPM-115, our high-dose exenatide implant for chronic weight management in obese
- Prev
- 1
- Next